Results 61 to 70 of about 28,682 (177)

Unveiling the Burden of Leukemia in Eritrea (2010–2020): Chronic Leukemia Stability, Rising ALL Incidence, and the Enigma of CML in a Low‐Resource Setting

Cancer Reports, Volume 8, Issue 6, June 2025.
ABSTRACT Background and Aims Little research has been conducted on the epidemiology of leukemia in Eritrea. In this retrospective study, we evaluated the burden and trends of acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), and overall leukemia in Eritrea ...
Daniel Mebrahtu Abraha, Samuel Tekle Mengistu, Efriem Ghirmay, Eden Gebresilassie, Ghirmay Embaye Zerat, Rahwa Kokob, Asmeret Tesfazghi, Solomon Negash, Tsega Daniel, Salih Mohammed, Oliver Okoth Achila   +10 more
wiley   +1 more source

Red blood cell distribution width at diagnosis as a predictor factor in chronic phase-chronic myeloid leukemia patients treated with first-generation tyrosine kinase inhibitors

Iraqi Journal of Hematology, 2023
BACKGROUND: Chronic myelogenous leukemia is a hematological disorder of stem cells resulting from uncontrolled and unregulated growth of myeloid cells in the bone marrow.
Raghad Nabeel Abdul-Latif, Asaad A Khalaf, Adel S Aqabi   +2 more
doaj   +1 more source

Novel clinical trial designs emerging from the molecular reclassification of cancer

CA: A Cancer Journal for Clinicians, Volume 75, Issue 3, Page 243-267, May/June 2025.
Abstract Next‐generation sequencing has revealed the disruptive reality that advanced/metastatic cancers have complex and individually distinct genomic landscapes, necessitating a rethinking of treatment strategies and clinical trial designs. Indeed, the molecular reclassification of cancer suggests that it is the molecular underpinnings of the disease,
Mina Nikanjam, Shumei Kato, Teresa Allen, Jason K. Sicklick, Razelle Kurzrock   +4 more
wiley   +1 more source

Detection of derivative 9 deletion by BCR-ABL fluorescence in-situ hybridization signal pattern to evaluate treatment response in CML patients [PDF]

Archive of Oncology, 2009
Background: To evaluate prognostic effect of submicroscopic deletions involving breakage and fusion points of the derivative chromosome 9 and 22 in chronic myeloid leukemia in untreated patients and their follow up samples to correlate with disease ...
Bakshi Sonal R., Shah Pankaj M., Shukla Shilin N., Dalal Esha N., Iyer Ramesh R., Brahmbhatt Manisha M., Gajjar Sarju B., Trivedi Pina J., Patel Beena P.   +8 more
doaj   +1 more source

α‐Synuclein in Parkinson's Disease: From Bench to Bedside

Medicinal Research Reviews, Volume 45, Issue 3, Page 909-946, May 2025.
ABSTRACT α‐Synuclein (α‐syn), a pathological hallmark of PD, is emerging as a bridging element at the crossroads between neuro/immune‐inflammatory responses and neurodegeneration in PD. Several evidence show that pathological α‐syn accumulates in neuronal and non‐neuronal cells (i.e., neurons, microglia, macrophages, skin cells, and intestinal cells ...
Gabriele Bellini, Vanessa D'Antongiovanni, Giovanni Palermo, Luca Antonioli, Matteo Fornai, Roberto Ceravolo, Nunzia Bernardini, Pascal Derkinderen, Carolina Pellegrini   +8 more
wiley   +1 more source

Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia-positive and negative acute lymphoblastic leukemia. [PDF]

PLoS ONE, 2014
Nilotinib is a selective BCR-ABL tyrosine kinase inhibitor related to imatinib that is more potent than imatinib. Nilotinib is widely used to treat chronic myelogenous leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). The
Hailong Zhang, Lubing Gu, Tao Liu, Kuang-Yueh Chiang, Muxiang Zhou   +4 more
doaj   +1 more source

Progression significance for low‐level aberrant B‐lymphoblasts in chronic myeloid leukaemia patients

Clinical and Translational Medicine, Volume 15, Issue 11, November 2025.
Haoren Wang, Huijun Wang, Yuanyuan Li, Bin Zheng, Qiuyun Fang, Yan Li, Yuntao Liu, Runxia Gu, Ying Wang, Yingchang Mi, Bingcheng Liu, Hui Wei, Jianxiang Wang   +12 more
wiley   +1 more source

Chlorogenic Acid: An In‐Depth Review of Its Effectiveness in Cancer Treatment

Cancer Nexus, Volume 1, Issue 1, April 2025.
ABSTRACT Cancer remains a formidable global health challenge. Owing to the unsatisfactory curative effects and severe side effects, it is urgent to explore safer and more effective therapeutic alternatives and drugs. Chlorogenic acid (CGA), a natural polyphenol, has emerged as a promising candidate for cancer therapy due to its multiple functions and ...
Bin Wang, Na Yin, Xinrui Liu, Yang Bai, Yue Cao, Ziqian Wang, Shiqi Bai, Shaopeng Zhang, Wanying Li, Yinghui Wang   +9 more
wiley   +1 more source

A Case of Hepatocellular Carcinoma after Treatment for Chronic Myeloid Leukemia in a Patient without Liver Disease

Case Reports in Oncology
Introduction: Chronic myeloid leukemia (CML) is a myeloproliferative disease caused by the reciprocal translocation of chromosomes 9 and 22, which leads to a chimeric gene product known as BCR-ABL.
Darshankumar M. Raval, Ricardo J. Pagán, Shayan Butt, Libardo Rueda Prada   +3 more
doaj   +1 more source

P210 and P190 BCR-ABL fusion transcripts variants frequencies among Philadelphia chromosome-positive chronic myeloid leukemia in Sudan

International Journal of Biomedical Research, 2018
Breakpoint cluster region-abelson (BCR-ABL) leukemic fusion gene types in chronic myeloid leukemia (CML) correlate with the disease clinical course and outcome.
A. A. Elnour, M. A. Abdalla
semanticscholar   +1 more source